The epidemiology of infections after living donor liver transplantation (LDLT) is limited. We aimed to study the epidemiology and risk factors of infections after LDLT. The medical records of 223 adult patients who underwent LDLT from January 1, 2000 to August 31, 2015 were reviewed for all infections occurring up to 1 year. We estimated the cumulative incidence of infection using the Kaplan-Meier product limit method. Risk factors were analyzed with time-dependent Cox regression modeling. The majority of patients were Caucasian (94.6%) and male (64.6%), and the median age at transplantation was 55 years. The most common indication for transplantation was primary sclerosing cholangitis (37.7%). A total of 122 patients developed an infection during the follow-up period (1-year cumulative event rate of 56%), with the majority (66%) of these occurring within 30 days after transplantation. Enterococcus sp. was the most frequent pathogen identified. Multivariate analysis showed that increased Model for End-Stage Liver Disease (MELD) score (per 10-point change: hazard ratio [HR], 1.59), history of recurrent infections prior to transplant (HR, 2.01), Roux-en-Y anastomosis (HR, 2.37), increased log-number of packed red blood cell transfusions (HR, 1.39), and biliary complications (HR, 4.26) were independently associated with a higher risk of infection. Infections occur commonly after LDLT, with most infections occurring early and being related to the hepatobiliary system. Higher MELD scores, the type of biliary anastomosis, presence of biliary complications, and prior pretransplant infections are independently associated with a higher risk for infections.
Liver transplantation has evolved as a highly effective, lifesaving approach to treat many end-stage liver diseases, (1) (2) (3) with a 1-year survival rate exceeding 80% in most transplant centers based on data from the Organ Procurement and Transplantation Network (OPTN).
In the United States, the vast majority of liver transplant procedures use organs from altruistic consenting deceased individuals. Living donors provide a viable alternative and an important source of hepatic allografts, especially due to organ shortage and limited donor availability. However, on the basis of data from the OPTN as of April 30, 2016 , there have only been 5776 living donor liver transplantations (LDLTs) performed compared with 136,732 deceased donor liver transplantations (DDLTs). In Asia, by contrast, where organ donation among deceased individuals is uncommon, leading to a critical shortage of organs, LDLT is performed more commonly. (4) Infection is a major complication that causes significant morbidity and mortality after liver transplantation. Despite advances in surgical techniques, immunosuppression, and infection prevention and control strategies, liver transplant recipients are at high risk for infection, with estimates of up to 80%. (5) (6) (7) The epidemiology and outcomes of these infections are well Abbreviations: BSI, bloodstream infection; CDI, C. difficile infection; CI, confidence interval; CLABSI, central-line associated bloodstream infection; CMV, cytomegalovirus; D, donor; DDLT, deceased donor liver transplantation; FFP, fresh frozen plasma; HB, hepatobiliary; HR, hazard ratio; ICU, intensive care unit; IQR, interquartile range; LDLT, living donor liver transplantation; MDRO, multidrug-resistant bacterial organism; MELD, Model for EndStage Liver Disease; MMF, mycophenolate mofetil; NASH, nonalcoholic steatohepatitis; OPTN, Organ Procurement and Transplantation Network; PRBC, packed red blood cell; PSC, primary sclerosing cholangitis; R, recipient; RBC, red blood cell; SOT, solid organ transplantation; SSI, surgical site infection; UTI, urinary tract infection; VRE, vancomycin-resistant Enterococcus.
described in the literature, particularly in the setting of DDLT. In contrast to the numerous reports that have described infectious complications after DDLT, studies describing the epidemiology and risk factors for infection specific to LDLT recipients have been very limited especially among the centers in the United States. Often, infections after LDLT are included in the overall liver transplant population (which consists mostly of DDLTs). To have a better understanding of the epidemiology and outcomes, we therefore aimed to describe the incidence and define the risk factors for infections that occur within the first year after LDLT.
Patients and Methods

PATIENT SELECTION
All patients who underwent LDLT at the Mayo Clinic, Rochester, MN, from January 1, 2000 to August 31, 2015, were eligible for inclusion in the study. As per Minnesota statute, only those who provided informed consent to allow review of their medical records for research purposes were included. The study proceeded only after approval from the institutional review board. Pediatric recipients < 18 years old or those who died during the day of transplantation were excluded from the study. Patients who were retransplanted within the first year were followed from date of first transplant (eg, day 0) only until time of retransplantation. The hospital transplant database and electronic health records were reviewed for relevant clinical and laboratory data regarding all infections from the date of transplant until 1 year later.
DEFINITIONS
Infections were defined using established criteria. (8) Infections were classified according to pathogen type (eg, bacterial, fungal, viral), and/or according to anatomic site (eg, respiratory/pneumonia, hepatobiliary [HB], surgical site, etc). The terms "microbiological" versus "syndromic" were also used to differentiate infections with microbiological evidence (eg, laboratory-based evidence or positive cultures) from those with clinical or radiographic evidence alone (eg, pneumonia, ascending cholangitis) with no confirmatory cultures.
Infections were classified as originating from the HB tree when recipients presented with the clinical syndrome of fever, jaundice, or right upper quadrant pain, relieved by biliary manipulation (eg, stenting and or dilation). Cultures taken from the HB site of patients presenting with compatible symptoms in the presence or absence of bacteremia fulfilled the criteria for microbiologically defined HB infection. Recurrent infection was defined as 2 or more bacterial infections occurring in the year prior to the date of transplantation. HB complications were defined as any complication involving the biliary tree, including biliary leak, stricture, stenosis, or bilomas.
ANTIMICROBIAL PROPHYLAXIS
Throughout the study period, all LDLT recipients received perioperative bacterial prophylaxis for 48 hours following transplantation with cefotaxime (1-2 g intravenously every 8 hours). The combination of ciprofloxacin plus vancomycin was used for patients with allergies, based on our institution's protocol. Herpes simplex virus antiviral prophylaxis consisted of acyclovir (177/221). Cytomegalovirus (CMV) prophylaxis was provided to CMV donor positive/recipient negative mismatches-oral ganciclovir (n 5 4) was available only until 2004, after which valganciclovir was used (n 5 40). CMV nucleic acid testing was performed weekly for CMV-seropositive transplant recipients, and CMV reactivation (defined as 5000 copies/mL of blood) was treated preemptively with intravenous ganciclovir or oral valganciclovir. Standard antifungal prophylaxis was with oral nystatin solution (163/196), unless recipients were considered high risk. High-risk recipients included recipients with prolonged surgery (>6 hours), those who received multiple packed red blood cell (PRBC) transfusions (10 units), those who required renal replacement therapy at/or after transplantation, those who had a major reoperation within 30 days of initial LT or were retransplanted, or developed fulminant hepatic failure. Recipients that met any of the clinical criteria were given either fluconazole (29/196) , itraconazole (1/196) , or an echinocandin (3/196) , depending on provider preference. Trimethoprim-sulfamethoxazole (179/215) was the Pneumocystis jiroveci pneumonia prophylaxis of choice. Pentamidine inhalation was given monthly for 6 months to those who were sulfa-allergic. All LDLT recipients from 2000 to 2013 (173/223) also received oral selective bowel decontamination consisting of a mixture of gentamicin, polymyxin, and nystatin, beginning at least 2 days before liver transplantation and discontinued at the time of dismissal from the initial hospitalization per protocol.
PRETRANSPLANT VANCOMYCIN-RESISTANT ENTEROCOCCUS SCREENING
Screening for vancomycin-resistant Enterococcus (VRE) prior to transplantation was done as part of the institution's protocol from January 2000 until March 2007. Of the 140 LDLT recipients during that period, screening was performed on 108 patients, and 14 were positive for VRE. Thereafter, screening for VRE prior to transplantation was discontinued.
IMMUNOSUPPRESSION
All patients initially received standard triple immunosuppressive regimen, consisting of prednisone, tacrolimus (alternative, cyclosporine in 5 patients), and mycophenolate mofetil (MMF). No T-lymphocytedepleting agents were given for induction. Basiliximab (15/223) was used as an alternative agent (in addition to prednisone and mycophenolate) for patients with renal insufficiency (creatinine 2.0 mg/dL or higher; creatinine clearance < 40 mL/minute; or dialysis requirement) and thus unable to take tacrolimus or cyclosporine. The protocol aimed to discontinue MMF at 2-4 months and taper off prednisone at 3 months, such that patients remained only on tacrolimus monotherapy by 4 months after LDLT, unless a patient needed intensified immunosuppression due to history of rejection or subtherapeutic tacrolimus or cyclosporine levels.
SURGICAL TECHNIQUE
All donor and recipient surgeries were performed by separate surgical teams. In general, the recipient was brought to the operating room for appropriate induction with general anesthesia once procurement of the donor liver was in process. After standard asepsis and preparation, a primary bilateral subcostal incision was made and extended in the midline. The liver was then mobilized with dissection and cautery. Once fully mobilized, the main portal vein was occluded and right and left branches were divided to begin the anhepatic phase. The recipient liver was then removed, preserving as much length of the hepatic veins as possible. The donor allograft was then placed in the abdominal cavity to determine the most appropriate site of hepatic venous anastomosis. Thereafter, the portal vein anastomosis was constructed, followed by arterial reconstruction. When necessary, an interposition or jump graft was used. The biliary anastomosis was performed last, via construction of a Roux-en-Y limb or a direct ductto-duct anastomosis, based on surgical feasibility and preference. After ensuring bile production and appropriate hemostasis, the incision was closed and the patient brought to the postanesthesia care unit for observation.
STATISTICAL ANALYSIS
Descriptive statistics on baseline variables were reported as frequency (percentage) for categorical variables and as quartiles (median, 25th and 75th percentiles; minimum and maximum) for continuous variables. For infection and other outcome variables, cumulative event rates were estimated as a function of time during the first year after transplantation using the Kaplan-Meier product limit method. In this calculation, those free of a given event were censored at the 1-year mark or, if earlier, at the time of their last follow-up visit. To assess patterns of 1-year infection among factors collected at baseline and during early follow-up, the Andersen-Gill counting process formulation of the Cox model was used. This facilitates the use of time-dependent covariates for nonbaseline factors, which are allowed to change value over follow-up time in the form of step functions. Selected a priori based on clinical importance, the set of candidate predictor variables was reduced in number to be in reasonable balance with the total number of infections, thereby reducing the risk of overfitting. To explore the possibility that risk factors differed according to type of infection, a sensitivity analysis was performed with bacterial infection modeled as the outcome variable. The number of CMV infections was deemed insufficient to support meaningful multivariate modeling, and thus only univariate associations are described. All data analyses were performed using SAS statistical software, version 9.4 (SAS Institute, Cary, NC).
Results
A total of 229 patients who received a LDLT during the study period were reviewed for study eligibility. Of these, 6 patients were excluded (2 were pediatric patients, 2 died the day of the transplant, and 2 others did not consent to the use of their medical records for research), leaving 223 included in the final analysis.
CHARACTERISTICS OF THE STUDY COHORT
Of the 223 patients, the majority were Caucasian (94.6%) and male (64.6%). The median age of the population was 55 years (range, 18-72 years). The most common indications for transplantation were primary sclerosing cholangitis (PSC; 37.7%) followed by nonalcoholic steatohepatitis (NASH; 11%) and chronic hepatitis C (11.2%). The clinical and demographic characteristics of the patient population and the details of the LDLT are summarized in Table 1 .
INFECTIOUS COMPLICATIONS
A total of 122 patients developed at least 1 infectious complication within the first year of transplantation, corresponding to a 1-year event rate of 56.3%. A total of 13 of these 122 patients experienced multiple infections during 1-year follow-up, for a total number of 135 infections. The vast majority of infections could be microbiologically defined (n 5 118; 87%), whereas only a minority was classified as syndromic (n 5 17, 13%). Most of the syndromic infections were HB infections (n 5 12; 71%), whereas the remaining were Varicella zoster reactivation (n 5 3; 18%), probable bacterial pneumonia (n 5 1; 6%), and culture-negative wound infection (n 5 1; 6%). Microbiologically confirmed infections were predominantly caused by bacteria (99/118; 84%). The most common source of these infections was the HB tract (55/99; 56%). The breakdown of infections according to category is outlined in Fig. 1 .
Timing of Infections
Risk of infection overall was markedly higher during the early period after LDLT, the majority (80/135; 59%) of these infections occurring within the first 30 days of transplantation (Table 2) . On the basis of Kaplan-Meier estimates, 1-, 6-, and 12-month cumulative event rates for first-time infection of any type were 37%, 51%, and 56%, respectively (Fig. 2 ).
Bacterial and Fungal Infections
The vast majority of infections were caused by bacteria. Cultures of clinical samples were polymicrobial in more than one-third of infections (38/99; 38%). Among cultures with monomicrobial growth, Enterococcus sp. was the most frequently isolated pathogen (19/61; 31%) followed by Escherichia coli (9/61; 15%; Table 2 ). Only a quarter of these bacterial infections were multidrug-resistant organisms (16/61; 26%): 6 were VRE; 2 were Methicillin-resistant Staphylococcus epidermidis; 4 were Methicillin-resistant Staphylococcus aureus; 3 were extended spectrum beta-lactamaseproducing gram-negative Enterobacteriaceae; and 1 was a carbapenem-resistant bacteria. The frequency of monomicrobial bacterial infections, grouped by whether or not they were multidrug-resistant organisms, is displayed annually across the study period in Fig. 3 .
Only 3 fungal infections occurred within 16-46 days after transplant. Two of these were due to Candida albicans isolated from a perirectal and HB source. The third case was disseminated infection from Coccidioides immitis.
Viral Infections
Only 19 viral infections occurred during the first year, with the majority (16/19; 84%) due to CMV. Of these, CMV disease was diagnosed in 9 patients, including 8 with gastrointestinal disease; 1 was consistent with CMV syndrome (Table 2 ). The median onset of CMV infection was 78.5 days (range, 36-218 days) from date of transplant. The remaining 3 viral infections were clinically diagnosed cutaneous Varicella zoster virus reactivation, occurring between 119 and 211 days after transplantation.
RISK FACTORS FOR INFECTION
As illustrated in Fig. 4 , there was evidence of an increasing trend in infections across the study period, particularly in more recent years (1-year infection rate of 75% for patients in whom transplant was performed during 2013-2015, compared with rates ranging from 47% to 56% for those in earlier transplant year groupings). Multivariate analysis ( 
Discussion
This study illustrates the common occurrence of infectious complications after LDLT. Across 1-year followup, more than half of our cohort developed at least 1 infection, and this is comparable with the reported 60%-80% infection rate in other studies of LDLT recipients. (9, 10) The rate of infection appears to be similar to DDLT recipients, (5) (6) (7) although studies that have directly compared their incidences are still lacking. The underlying reasons why liver transplant recipients are more vulnerable (compared with other solid organ transplantation [SOT] recipients) could be due to the technical complexity of surgery, contamination in the abdominal cavity, and poor premorbid host condition. NOTE: Data are given as n (%) or median (IQR) [range]. *Cumulative incidence at 1-year follow-up is reported as total number of events followed by the event rate (percentage derived by the Kaplan-Meier product limit estimator) in parentheses.
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Most infections occurred within the early period (eg, 30 days) and were predominantly due to bacteria of HB origin. (10, (12) (13) (14) This observation indicates that the risk is associated with the technically difficult surgery. LDLT differs from DDLT in that issues unique to the procedure itself likely increase the risk for postoperative infection: first, the small-for-size donor grafts may lead to postoperative liver dysfunction with prolonged cholestasis and coagulopathy (known as small-for-size liver syndrome); second, biliary leakage from the cut surface of the graft may subsequently lead to biloma formation that may get secondarily infected; third, the surgical procedure for LDLT is technically more challenging and contributes to the higher incidence of complications such as biliary strictures. (15) (16) (17) Many studies have described the high rates of biliary complications stemming from this procedure. (18) (19) (20) (21) (22) (23) (24) Indeed, the predominant pathogens that we observed in this study were bacteria from the HB system. The most commonly isolated pathogens in this time period were either polymicrobial or Enterococcus sp. This is consistent with other reports where, over a time period of 3 months, intra-abdominal infections were common, with Enterococcus sp. and E. coli as the most frequently isolated pathogens. (10, 14) Bloodstream infection (BSI) due to bacteria was the second most common infectious complication in the early posttransplant period. Although a source was not identified in most cases, the pathogens isolated in the blood suggest either a skin or intra-abdominal source. In contrast to data on DDLT, where BSI is mostly catheter-related, (5, 25, 26) our data suggest a higher proportion of BSI from an intra-abdominal focus. (5) This confirms previous observations that surgical site and intra-abdominal infections were major sources of BSI. (27) Notably, surgical site infections (SSIs) did not feature prominently in our study.
We observed 10 cases of C. difficile infection (CDI; 4% of the 223 patients) throughout the 1-year period after LDLT. CDI has been reported among SOT, with incidences ranging from 3% to 19%. (28) (29) (30) (31) In 1 study of LDLT, (32) CDI occurred in 11 (5%) of 242 LDLT recipients. Several reasons for increased CDI risk are the frequent use of antibiotics (likely due to high rates of posttransplant bacterial infections), suppression of anti-inflammatory cytokines, suppression of antibody-mediated response to toxins, and longer and more frequent hospital admissions. (33) We only identified 3 fungal infections in this study. Two were early infections from Candida albicans, and the third was a case of disseminated coccidiomycosis. Previous studies have reported a high incidence of postoperative fungal infection ranging from 5% to 40%, with a high attributable mortality. (14) It is unclear why the rate of fungal infection was extremely low in our cohort, although universal antifungal prophylaxis with nystatin, use of oral bowel decontamination solution containing antifungals, and selective or targeted antifungal prophylaxis using an azole or an echinocandin for high-risk patients may have contributed to this low rate.
The cumulative incidence of CMV infection was low. It was distributed almost equally between early onset CMV reactivation among CMV-seropositive LDLT recipients who were not receiving antiviral prophylaxis, and late-onset primary CMV disease among CMV donor (D)1/recipient (R)-LDLT who completed 3-6 months of antiviral prophylaxis. Expectedly, on univariate analysis, being a CMV D1/R-mismatch was significantly associated with developing CMV reactivation. (34) Several independent risk factors were associated with infection on multivariate analysis. Pretransplant variables that increased risk of infection included higher MELD score and history of infections in the year prior to transplant. This is not unexpected because MELD score directly correlates with the severity of the preoperative clinical condition and mortality. (35, 36) In 1 prior study that included both LDLT and DDLT, (37) MELD > 20 was associated with early infection after transplantation. History of recurrent infections in the year prior to transplantation also appears to significantly increase the risk of infection in the first year after LDLT. A majority of those who had recurrent infections prior to transplant had underlying PSC whose diseased native biliary systems may have inherently increased their risk for HB infections and complications. We therefore propose that patients with underlying PSC and/or history of recurrent infections in the year prior to transplantation receive an individualized regimen for antimicrobial prophylaxis at the time of LDLT, taking into account their infection and colonization history. In this regard, we intend to modify the antimicrobial prophylaxis to include agents active against Enterococcus (the predominant pathogen in this study), such as penicillin, vancomycin, or daptomycin (depending on resistance information) in addition to gram-negative coverage.
The incidence of multidrug-resistant bacterial organisms (MDROs) in our cohort was extremely low, and this is consistent with our overall hospital infection control surveillance data. However, we demonstrate that the number of MDROs appears to be increasing over time and, as such, needs to be carefully monitored; this could eventually impact our antibacterial prophylaxis protocols and empiric treatment regimens. Should the upward trend continue, mandatory screening of donors and/or recipients for VRE or gram-negative MDROs prior to transplantation may become necessary. Currently, such a screening protocol is applied only to patients coming from high-risk regions of the country and the world.
Roux-en-Y choledochojejunostomy and biliary complications were independent risk factors for infection. Our institution is a referral center for treatment of PSC, and the higher proportion of recipients undergoing Roux-en-Y anastomosis reflects the majority of our patients with underlying PSC. Roux-en-Y is often the anastomosis of choice because the recipient's native extrahepatic bile duct is diseased and makes a duct-to-duct connection difficult. The higher number of infections with Roux-en-Y is not unexpected because the open connection between the intrahepatic bile ducts and the bowel lumen may result in ascending bacterial migration and recurrent cholangitis. (38) As discussed above, PSC is also associated with a higher risk of biliary complications, especially nonanastomotic strictures (39, 40) that often present at multiple locations in the biliary tree, are frequently resistant to therapy, may be progressive over time, (38, 41) and subsequently increase infection risk. Given the overrepresentation of PSC in our cohort, it is not surprising that the majority of infections were HB in origin and the risk factors for infection were directly related to surgery and the underlying disease state.
Receipt of a greater number of intraoperative PRBC transfusions as a risk factor for infection is consistent with prior studies (11, 14, 37) and is an indirect marker for the technically difficult intraoperative procedure in LDLT. Interestingly, a more recent year of transplantation almost reached statistical significance as a risk factor for overall infection, although this was not validated on multivariate analysis. The exact mechanism underlying this observation is not defined but could be influenced by several confounding factors, including transplantation of older and sicker patients. A post hoc analysis showed no evidence of a trend of increasing age at transplant over the study period, though patients who most recently underwent transplantation in 2013-2015 had a significantly higher MELD score than those in previous years (median score, 17 versus 13). Other risk factors associated with infection reported in prior studies (10, 14, 37, 42) including chronic renal insufficiency, prolonged intensive care unit (ICU) or hospital stay, and reoperation were not identified as risk factors in our cohort.
Our study has some limitations inherent to its retrospective nature. First, because the study spanned several years, certain changes in protocol and/or clinical practice may have inadvertently influenced infection rates. Second, data regarding infections may have been missed if they were not adequately described or coded in the electronic health record; likewise, information outside of the Mayo Clinic such as hospital admissions related to infection may not have been properly documented and captured. Third, we did not look at use of surrogate markers such as serum galactomannan and b-1,3 glucan that may have been used to diagnose fungal infections in the absence of culture data. Hence, we may have missed probable invasive fungal infections. Despite these limitations, our study is the first large cohort that investigated the epidemiology and risk factors for infection among LDLT recipients in the United States. We confirm a high incidence of bacterial infection especially in the first 30 days following transplantation. Most infections were HB in nature and related to surgery, highlighting the technically complex procedure unique to LDLT recipients. We identified higher MELD score, recent history of infection, and biliary complications as risk factors of infection.
